• Corpus ID: 6500315

Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster.

  title={Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster.},
  author={Meng-Chuan Shen and Hsi‐Hsun Lin and Susan Shin-Jung Lee and Yao Shen Chen and Ping-Chen Chiang and Yung-ching Liu},
  journal={Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi},
  volume={37 2},
This randomized, double-blind, parallel-group study compared the efficacy and safety of famciclovir administered at 250 mg thrice daily with acyclovir 800 mg 5 times daily for the treatment of acute uncomplicated herpes zoster in immunocompetent adults. [] Key Result A total of 55 patients participated in this trial. Twenty seven patients (49.1%) were randomized into the famciclovir plus placebo treatment group and 28 (50.9%) into the acyclovir plus placebo group.

Figures and Tables from this paper

A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster.

Oral famciclovir administered three times daily for 7 days during acute zoster infection is as effective as acyclovir, administered 800mg five times daily and offers significant benefit by providing a well tolerated, cost effective, convenient dosage regime and accelerated rate of lesion resolution and a reduced duration of PHN.

A Comparative Study Of Famciclovir Versus Acyclovir In The Treatment Of Herpes Zoster

Safety profile and complete healing were comparatively better in famciclovir group Itroduction: Herpes zoster (HZ) (shingles) is a disease of great antiquity known since ages and is caused by varicella zoster virus which also causes a different clinical entity varICElla.

Comparative Study of Oral Acyclovir and Oral Famciclovir in the treatment of Herpes Zoster

Famciclovir can be a better option in the treatment of herpes zoster in view of all the above mentioned facts and it has got a convenient dosage schedule as well.

Pharmacokinetics and Safety of Famciclovir in Children with Herpes Simplex or Varicella-Zoster Virus Infection

An eight-step weight-based dosing regimen was developed to optimize exposure in smaller children and was used in the 7-day multiple-dose safety phases of both studies, which enrolled 100 patients with confirmed/suspected viral infections.

Antivirals for Management of Herpes Zoster Including Ophthalmicus: A Systematic Review of High-Quality Randomized Controlled Trials

Evidence from quality trials have shown significant reduction in risk of pain with valaciclovir and famciclovIR for management of herpes zoster including ophthalmicus.

Single-Dose Pharmacokinetics of Famciclovir in Infants and Population Pharmacokinetic Analysis in Infants and Children

The data suggested that the dose administered to infants <6 months was less than optimal, and an eight-step dosing regimen was derived that targeted exposure in infants and children 6 months to 12 years of age to match the penciclovir AUC seen in adults after a 500-mg dose of famcic Lovir.

Treatment of herpes zoster.

There is no convincing evidence that antiviral medication reduces the risk of PHN, and these drugs should be prescribed to all patients at the first signs of ophthalmic HZ, irrespective of age or severity of symptoms.

Current Management of Herpes Zoster

Use of antiviral therapy including the newer potent antiviral agents such as brivudin, which requires less frequent administration than acyclovir, is improving patient outcomes in some European countries and, as a result, overall antiviral use is low.

Efficacy of famciclovir in the treatment of oral hairy leukoplakia

It is suggested that more targeted treatment for cGVHD will be necessary before resolution of the angiomas is obtained, because treatment has been recalcitrant in all cases and it appears to have a poor prognosis.



Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

Famciclovir, a new antiviral agent, was approved for marketing by the Food and Drug Administration in June 1994 for the management of acute herpes zoster and its effect on postherpetic neuralgia remains controversial.

Pharmacokinetics of Famciclovir in Man

The results of a number of studies conducted in healthy volunteers indicate that famciclovir possesses excellent pharmacokinetic properties for the provision of clinically useful concentrations of the antiviral agent pencic Lovir in the oral treatment of herpesviral infections.

An Overview of the Further Evaluation of Penciclovir against Herpes Simplex Virus and Varicella-Zoster Virus in Cell Culture Highlighting Contrasts with Acyclovir

The antiviral action of penciclovir against herpes simplex virus (HSV) and varicella-zoster virus (VZV) in cell culture is reviewed and there was marked synergy between pencIClovir and HuIFN-α and HuifN-β against HSV-1 andHSV-2 and possible clinical implication of these results are discussed.

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

A biochemical rationale for the highly selective and effective inhibition of HSV-2 and VZV DNA synthesis by penciclovir is provided and for the greater activity of pencIClovir than that of acyclovir when HSv-2-infected cells were treated for a short time.

Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern

Both compounds were highly selective antiviral agents with minimal effects on a wide range of representative, proliferating human cells, and the mechanism of action of penciclovir has been investigated.

Comparative efficacy of antiherpes drugs in different cell lines.

A selection of antiherpes compounds including bromovinyldeoxyuridine (BVDU), acyclovir (ACV), and fluoroiodoaracytosine (FIAC) were compared for their inhibitory effects on herpes simplex virus type

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

BRL 39 123 was shown to be more effective than acyclovir at inhibiting viral DNA synthesis following short treatment times, presumably reflecting the greater stability of BRL 39123 triphosphate.

In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2

HSV-infected cultures receiving 2-h pulses ofPCV had 2- to 50-fold less HSV than acyclovir-treated cultures, consistent with the prolonged intracellular half-life of PCV triphosphate.

Confidence intervals for reporting results of clinical trials.

  • R. Simon
  • Medicine
    Annals of internal medicine
  • 1986
Confidence intervals are important but underused supplements to tests of significance for reporting the results of clinical investigations, and formulas are presented for calculating confidence intervals with types of data commonly found in clinical trials.